Drug Supply During COVID-19 Pandemic: Remember Not to Run With Your Tank Empty

Deana, Cristian; Vetrugno, Luigi; Tonizzo, Alessandra; Orso, Daniele; Piani, Tommaso; Bove, Tiziana; Monte, Amato De

doi:10.1177/0018578720931749

Cited by 6 publications

(4 citation statements)

References 8 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to be effective and timely, we limited the scope of our work to the report to the inpatient therapeutic environment, allowing other committees to work on other aspects of the pandemic response. In addition to issuing guidance and creating order sets to direct clinical practice, the CCMC also monitored COVID-19 therapeutic shortages 15,16 and advised on prioritization of such treatments as convalescent plasma, remdesivir (prioritization and duration of therapy, 5 vs 10 days), baricitinib, and tocilizumab, depending upon the location of the patient (critical care or not). The CCMC was not involved in the management of non-COVID-19 shortages brought about by supply chain deficiencies.…”

Section: Scope Of Ccmcmentioning

confidence: 99%

A COVID-19 Clinical Management Committee to Standardize Care in a 2-Hospital System

Meisenberg¹

2022

JCOM

View full text Add to dashboard Cite

The COVID-19 pandemic has been a challenge for hospital medical staffs worldwide due to high volumes of patients acutely ill with novel syndromes and prevailing uncertainty regarding optimum supportive and therapeutic interventions. Additionally, the response to this crisis was driven by a plethora of nontraditional information sources, such as email chains, websites, non-peer-reviewed preprints, and press releases. Care patterns became idiosyncratic and often incorporated unproven interventions driven by these nontraditional information sources. This report evaluates the efforts of a health system to create and empower a multidisciplinary committee to develop, implement, and monitor evidence-based, standardized protocols for patients with COVID-19.Methods: This report describes the composition of the committee, its scope, and its important interactions with the health system pharmacy and therapeutics committee, research teams, and other work groups planning other aspects of COVID-19 management. It illustrates how the committee was used to demonstrate for trainees the process and value of critically examining evidence, even in a chaotic environment.Results: Data show successful interventions in reducing excessive ordering of certain laboratory tests, reduction of nonrecommended therapies, and rapid uptake of evidencebased or guidelines-supported interventions.Conclusions: A multidisciplinary committee dedicated solely to planning, implementing, and monitoring standard approaches that eventually became evidence-based decision-making led to an improved focus on treatment options and outcomes for COVID-19 patients. Data presented illustrate the attainable success of a committee that is both adaptable and suitable for similar emergencies in the future.

show abstract

Section: Scope Of Ccmcmentioning

confidence: 99%

A COVID-19 Clinical Management Committee to Standardize Care in a 2-Hospital System

Meisenberg¹

2022

JCOM

View full text Add to dashboard Cite

show abstract

“…It not only directly impacts the COVID-19 patient but also poses a risk to the health and safety of patients who are suffering from other disorders (Choo & Rajkumar, 2020) Hospitals require reliable stock information and anticipated supply chain bottlenecks to prepare for the medicine shortage adequately. Consumption rates should be thoroughly analyzed and routinely audited by users (hospital pharmacies) (Deana et al, 2020). Hospital pharmacies in outbreak-affected and unaffected areas play a crucial role in ensuring enough storage and supply of required medications and other medical items and devices to fulfill demand, including masks, thermometers, goggles, and other needed equipment (Federation International Pharmaceutical, 2020).…”

Section: Introductionmentioning

confidence: 99%

Differences in the Use of Covid-19 Comorbid Drugs in Before and Early Of Pandemic

Skarayadi¹,

Syarifuddin²,

Ramdhani³

et al. 2022

midwifery

View full text Add to dashboard Cite

Comorbid patients with Covid 19 affect the severity of the infection. This study aims to examine the utilization of generic medications in the treatment of comorbid Covid-19. Data were retrieved retrospectively from Al Ihsan Hospital's medical records. The data summarize the use of generic medicines for comorbid Covid-19 in the year preceding and in the first year of the pandemic. Metformin is the most commonly recommended medication for type 2 diabetes management.In contrast, Acarbose was the most extensively used medicine before the epidemic. Pioglitazone is the least prescribed diabetes medication. Before the pandemic, Amlodipine 10 mg was the most commonly prescribed medication for cardiovascular disease management. This is distinct from the pre-pandemic period when Ramipril was the most frequently used medication. Verapamil was the least prescribed medication prior to and throughout the epidemic. Three of the eleven medicine names analyzed in the Diabetes Comorbid group indicated that there was a significant variation in use between before and during the pandemic. Thirteen of the twenty-one medicine names analyzed in the Cardiovascular Comorbid group showed a substantial variation in usage between before and during a pandemic.

show abstract

“…The supply chain of COVID-19 vaccines is not capable to provide global immunization on short time. In addition, medical products, such as ventilators and sedative drugs, had their demand increased drastically during pandemic, and their supply chain were strained, causing shortage in many regions 7 , 8 , 9 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy and sustainability of natural products in COVID-19 treatment development: opportunities and challenges in using agro-industrial waste from Citrus and apple

Antonio

Wiedemann

Galante

et al. 2021

Heliyon

View full text Add to dashboard Cite

Natural products have been used in the treatment of illnesses throughout the history of humankind. Exploitation of bioactive compounds from natural sources can aid in the discovery of new drugs, provide the scaffold of new medicines. In the face of challenging diseases, such as the COVID-19 pandemic, for which there was no effective treatment, nature could offer insights as to novel therapeutic options for control measures. However, the environmental impact and supply chain of bioactive production must be carefully evaluated to ensure the detrimental effects will not outweigh the potential benefits gained. History has already proven that highly bioactive compounds can be rare and not suitable for medicinal exploitation; therefore, the sustainability must be accessed before expensive, time-demanding, and large trials can be initialized. A sustainable option to readily produce a phytotherapy with minimal environmental stress is the use of agro-industry wastes, a by-product produced in high quantities. In this review we evaluate the sustainability issues associated with the production of phytotherapy as a readily available tool for pandemic control.

show abstract

Drug Supply During COVID-19 Pandemic: Remember Not to Run With Your Tank Empty

Cited by 6 publications

References 8 publications

A COVID-19 Clinical Management Committee to Standardize Care in a 2-Hospital System

A COVID-19 Clinical Management Committee to Standardize Care in a 2-Hospital System

Differences in the Use of Covid-19 Comorbid Drugs in Before and Early Of Pandemic

Efficacy and sustainability of natural products in COVID-19 treatment development: opportunities and challenges in using agro-industrial waste from Citrus and apple

Contact Info

Product

Resources

About